Workflows for GLP-1 Receptor Agonists and Therapeutic Peptides
White Papers10 Jul 2026
Sponsored by Agilent
The global peptide drug market is expanding rapidly, with over 110 approved products as of 2024. Metabolic diseases, particularly type 2 diabetes and obesity, remain the largest segment, driven by glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
This compendium provides practical insights and workflows for GLP-1 RAs and related peptides, addressing analytical challenges from identity verification to impurity characterization and bioanalysis.
Download Now
Related Content
Accelerating Personalised Medicine with Digital ManufacturingSPONSORED ARTICLE
Analysis of a Synthetic Peptide and its ImpuritiesSPONSORED ARTICLE
Aseptic Filling by Design: Shaping the Future of Drug ManufacturingSPONSORED ARTICLE
Cleanroom Apparel RequirementsSPONSORED ARTICLE
Confidently Choosing the Right Development PathSPONSORED ARTICLE
Controlling image quality in diagnostic displaysSPONSORED ARTICLE
Discover How Aenova Can De-Risk Your Drug DevelopmentSPONSORED ARTICLE
Supply Chain Talk
view all
Wednesday, 23 Sep 2026
Turning supply chain orchestration into a competitive and financial advantage
Wednesday, 30 Sep 2026
Maximising Uptime - How AI & asset visibility are transforming operations
Wednesday, 07 Oct 2026
Build resilience: Turning uncertainty into opportunity with AI-driven risk management
Winston House, 3rd Floor,
Units 306-309, 2-4 Dollis park,
London, N3 1HF
020 8349 4363
© 2026, Lyonsdown Limited. teiss® is a registered trademark of Lyonsdown Ltd. VAT registration number: 830519543